Zacks Research Boosts Omnicell Q1 Earnings Forecast

Analysts raise estimates for the healthcare technology company's upcoming quarterly results.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Research analysts at Zacks Research have increased their Q1 2026 earnings per share estimates for Omnicell, Inc. (NASDAQ:OMCL). The firm now anticipates the company will earn $0.13 per share for the quarter, up from their previous forecast of $0.09. Zacks Research maintains a 'Strong Sell' rating on Omnicell's stock, while the consensus estimate for the company's current full-year earnings is $1.09 per share.

Why it matters

Omnicell is a leading provider of medication management solutions for healthcare facilities, so its quarterly earnings are closely watched by investors and analysts. The revised Q1 forecast from Zacks Research suggests the company may be performing better than previously expected, which could impact the stock price and investor sentiment.

The details

In a report released on February 26th, Zacks Research analysts increased their Q1 2026 earnings per share estimate for Omnicell from $0.09 to $0.13. The firm maintains a 'Strong Sell' rating on the stock, though the consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Several other analysts have also weighed in on the stock, with Bank of America upgrading it to 'buy' and increasing the price target, while Piper Sandler reiterated an 'overweight' rating.

  • Zacks Research released the updated Q1 2026 earnings forecast on Thursday, February 26th.

The players

Zacks Research

A research firm that provides investment research and stock analysis.

Omnicell, Inc.

A healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The revised Q1 earnings forecast from Zacks Research suggests Omnicell may be performing better than expected, which could impact the stock price and investor sentiment around the healthcare technology company.